Patents Assigned to Oregon Health & Science University
  • METHOD FOR SUBTYPING LYMPHOMA TYPES BY MEANS OF EXPRESSION PROFILING
    Publication number: 20200143906
    Abstract: The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.
    Type: Application
    Filed: January 17, 2020
    Publication date: May 7, 2020
    Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, British Columbia Cancer Agency Branch, Arizona Board of Regents on Behalf of the University of Arizona, Universitat de Barcelona, Hospital Clinic de Barcelona, The Cleveland Clinic Foundation, Board of Regents of the University of Nebraska, Oregon Health & Science University, Julius-Maximilians-University of Würzburg, Oslo University Hospital HF
    Inventors: Louis M. Staudt, George W. Wright, David William Scott, Joseph M. Connors, Randy D. Gascoyne, Lisa Rimsza, Elias Campo Guerri, Raymond Tubbs (Deceased), Timothy C. Greiner, James Robert Cook, Kai Fu, Paul Michael Williams, Chih-Jian Lih, Elaine S. Jaffe, Rita M. Braziel, Andreas Rosenwald, Erlend B. Smeland, Wing C. Chan, German Ott, Jan Delabie, Dennis Weisenburger
  • Systems and methods to remove shadowgraphic flow projections on OCT angiography
    Patent number: 10631730
    Abstract: Methods and systems for suppressing shadowgraphic flow projection artifacts in OCT angiography images of a sample are disclosed. In one example approach, normalized OCT angiography data is analyzed at the level of individual A-scans to classify signals as either flow or projection artifact. This classification information is then used to suppress projection artifacts in the three dimensional OCT angiography dataset.
    Type: Grant
    Filed: February 4, 2019
    Date of Patent: April 28, 2020
    Assignee: Oregon Health & Science University
    Inventors: David Huang, Yali Jia, Miao Zhang
  • Methods and compositions for modulating AAV infection
    Patent number: 10633662
    Abstract: Compositions and methods are provided for modulating adeno-associated virus (AAV) infection. For example, compositions and methods are provided for enhancing permissiveness of a target cell to AAV infection (e.g., by increasing levels of AAVR (KIAA0319L) in the cell), for reducing permissiveness of a target cell to AAV infection (e.g., by reducing levels of AAVR in the cell), and for nucleic acid delivery (e.g., by (i) increasing permissiveness of a target cell to AAV infection, e.g., by increasing the amount of AAVR in the cell; and (ii) contacting the target cell with an AAV particle that includes a nucleic acid of interest). Also provided are screening methods and kits for practicing the methods of the disclosure.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: April 28, 2020
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Oregon Health & Science University
    Inventors: Sirika Pillay, Jan Carette, Michael Stewart Chapman, Nancy Meyer, Andreas Puschnik, Omar Davulcu
  • COMPOUNDS AND METHODS USED IN ASSESSING MONO-PARP ACTIVITY
    Publication number: 20200123192
    Abstract: Mutant mono ADP-ribose-polymerases (mono-PARP) proteins and small molecule compound substrates specific for the mutant mono-PARP proteins as well as methods of using these compositions to identify protein targets of the mono-PARPs and to screen for antagonists of the mono-PARPs are described.
    Type: Application
    Filed: December 16, 2019
    Publication date: April 23, 2020
    Applicant: Oregon Health & Science University
    Inventors: Michael Cohen, Ian Carter-O'Connell, Rory Morgan, Haihong Jin
  • METHOD FOR DETERMINING LYMPHOMA TYPE
    Publication number: 20200105364
    Abstract: In embodiments of the invention, the invention provides a method for distinguishing between lymphoma types based on gene expression measurements. In embodiments, the invention distinguishes between PMBCL and DLBCL based on gene expression signatures, and can further distinguish between DLBCL subtypes. In embodiments of the invention, the distinctions are used in methods of treatment.
    Type: Application
    Filed: December 13, 2019
    Publication date: April 2, 2020
    Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, British Columbia Cancer Agency Branch, Mayo Foundation for Medical Education and Research, Julius-Maximilians-University of Würzburg, Board of Regents of the University of Nebraska, Oslo University Hospital HF, Hospital Clinic de Barcelona, Universitat de Barcelona, Institut D? Investigacions Biomèdiques August Pi I Sunyer (IDIBAPS), Robert Bosch Gesellschaft fuer medizinische Forschung mbH, Oregon Health & Science University, City of Hope, The Cleveland Clinic Foundation
    Inventors: Louis M. Staudt, Christian Steidl, Anja Mottok, George W. Wright, David William Scott, Lisa M. Rimsza, Andreas Rosenwald, Randy Gascoyne, Timothy Greiner, Dennis Weisenburger, Erlend B. Smeland, Jan Delabie, Elias Campo Guerri, German Ott, Rita Braziel, Elaine S. Jaffe, Kai Fu, Wing C. Chan, Joo Song, James R. Cook
  • Method for subtyping lymphoma types by means of expression profiling
    Patent number: 10607717
    Abstract: The invention is directed to methods for selecting a treatment option for an activated B cell-like diffuse large B cell lymphoma (ABC DLBCL) subject, a germinal center B cell-like diffuse large B cell lymphoma (GCB DLBCL) subject, a primary mediastinal B cell lymphoma (PMBL) subject, a Burkitt lymphoma (BL) subject, or a mantle cell lymphoma (MCL) subject by analyzing digital gene expression data obtained from the subject, e.g., from a biopsy sample.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: March 31, 2020
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, British Columbia Cancer Agency Branch, Arizona Board of Regents on behalf of the University of Arizona, Universitat de Barcelona, Hospital Clinic de Barcelona, The Cleveland Clinic Foundation, Board of Regents of the University of Nebraska, Oregon Health and Science University, Julius-Maximilians-University of Würzburg, Oslo University Hospital HF
    Inventors: Louis M. Staudt, George W. Wright, David William Scott, Joseph M. Connors, Randy D. Gascoyne, Lisa Rimsza, Elias Campo Guerri, Raymond Tubbs, Timothy C. Greiner, James Robert Cook, Kai Fu, Paul Michael Williams, Chih-Jian Lih, Elaine S. Jaffe, Rita M. Braziel, Andreas Rosenwald, Erlend B. Smeland, Wing C. Chan, German Ott, Jan Delabie, Dennis Weisenburger
  • Method for reducing ototoxicity in pediatric patients receiving platinum-based chemotherapy
    Patent number: 10596190
    Abstract: Described herein is a method for eliminating or reducing ototoxicity in patients receiving a platinum based chemotherapeutic. In particular, are methods of reducing ototoxicity in a pediatric patient. The methods described herein include administering an effective amount of sodium thiosulfate to a patient in need thereof to reduce ototoxicity.
    Type: Grant
    Filed: August 24, 2018
    Date of Patent: March 24, 2020
    Assignee: Oregon Health & Science University
    Inventor: Edward A. Neuwelt
  • Bulk motion subtraction in optical coherence tomography angiography
    Patent number: 10588572
    Abstract: Described herein is an algorithm to remove decorrelation noise due to bulk motion in optical coherence tomography angiography (OCTA). OCTA B-frames are divided into segments within which the bulk motion velocity could be assumed constant. This velocity is recovered using linear regression of decorrelation versus the logarithm of reflectance in axial lines (A-lines) identified as bulk tissue by percentile analysis. The fitting parameters are used to calculate a reflectance-adjusted threshold for bulk motion decorrelation. Below this threshold, voxels are identified as non-flow tissue, and their flow values are set to zeros. Above this threshold, the voxels are identified as flow voxels and bulk motion velocity is subtracted from each using a nonlinear decorrelation-velocity relationship.
    Type: Grant
    Filed: November 7, 2017
    Date of Patent: March 17, 2020
    Assignee: Oregon Health & Science University
    Inventors: Yali Jia, David Huang, Yan Li, Acner Camino
  • Quinolone-3-diarylethers
    Patent number: 10584098
    Abstract: Disclosed are derivative compounds of ELQ-300 that include an ester at position 4. These compounds have enhanced properties relative to ELQ-300. Also disclosed are pharmaceutical compositions comprising the compounds and methods of treating and preventing malaria infections involving administering the pharmaceutical compositions to the subject.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: March 10, 2020
    Assignee: Oregon Health & Science University
    Inventors: Michael Riscoe, Aaron Nilsen, Galen Miley, Rolf Winter, Sovitj Pou, Jane Xu Kelly, Rozalia Dodean
  • SYSTEMS AND METHODS FOR THE IDENTIFICATION OF PERIVASCULAR SPACES IN MAGNETIC RESONANCE IMAGING (MRI)
    Publication number: 20200074214
    Abstract: Disclosed herein are methods and systems for the identification and characterization of perivascular spaces in the cerebral vasculature using magnetic resonance imaging (MRI) data. The disclosed methods allow for automated and unbiased quantification of enlarged perivascular space (ePVS) in a subject, and thus can provide a substantial improvement over manual grading methods used in the art. An example method includes receiving an MRI dataset including voxels having intensity values, identifying a set of candidate voxels within the MRI dataset based on the intensity values; grouping the set of candidate voxels into a set of first clusters; filtering the set of first clusters to generate a set of second clusters; and filtering the set of second clusters based on a morphologic constraint, thereby identifying an enlarged perivascular space in the MRI dataset.
    Type: Application
    Filed: August 29, 2019
    Publication date: March 5, 2020
    Applicant: Oregon Health & Science University
    Inventors: Erin L. Boespflug, David Lahna, Daniel Schwartz, Lisa C Silbert
  • Anti-factor XI monoclonal antibodies and methods of use thereof
    Patent number: 10577428
    Abstract: Compositions and methods for inhibiting thrombosis without compromising hemostasis are described. Compositions include anti-factor XI monoclonal antibodies (aXIMabs) capable of binding to an epitope on the heavy chain of human FXI, particularly the A3 domain of the heavy chain of human FXI. Compositions also include epitope-binding fragments, variants, and derivatives of the monoclonal antibodies, cell lines producing these antibody compositions, and isolated nucleic acid molecules encoding the amino acid sequences of the antibodies. The disclosure further includes pharmaceutical compositions comprising the disclosed anti-factor XI monoclonal antibodies, or epitope-binding fragments, variants, or derivatives thereof, in a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: March 3, 2020
    Assignees: Oregon Health & Science University, Vanderbilt University
    Inventors: Andras Gruber, Erik I. Tucker, Stephen Raymond Hanson, David Gailani
  • COMBINATIONS OF AGENTS TO TREAT HEMATOLOGICAL MALIGNANCIES
    Publication number: 20200054639
    Abstract: Methods of treating acute myeloid leukemia, chronic lymphocytic leukemia and myeloproliferative neoplasms that involve the administration of combinations of small molecule compounds are disclosed.
    Type: Application
    Filed: October 31, 2017
    Publication date: February 20, 2020
    Applicant: Oregon Health & Science University
    Inventors: Jeffrey Tyner, Stephen Kurtz, Brian Druker, Elie Traer, Christopher Eide, Motomi Mori, Andrew Kaempf
  • DIAGNOSTIC CLASSIFICATION OF CORNEAL SHAPE ABNORMALITIES
    Publication number: 20200054208
    Abstract: Disclosed are systems and methods for characterizing corneal shape abnormalities. These methods may be used to differentiate corneas having subclinical keratoconus from other conditions which cause distortion of corneal shape, including warpage of the cornea due to contact lens wear. Also disclosed is classification scheme to aid diagnosis of corneal conditions and thereby guide clinical decision making regarding patient treatment. This classification scheme is based on computed properties of corneal shape, is amenable to automation, and may be implemented in an integrated system or provided in the form of software encoded on a computer-readable medium.
    Type: Application
    Filed: August 21, 2019
    Publication date: February 20, 2020
    Applicant: Oregon Health & Science University
    Inventors: Maolong Tang, Yan Li, David Huang
  • Synergistic co-administration of computationally optimized broadly reactive antigens for human and avian H5N1 influenza
    Patent number: 10548965
    Abstract: The present invention provides co-administration (e.g., immunogenic cocktail and/or prime-boost regimens) of computationally optimized H5N1 influenza hemagglutinin (HA) polypeptides that. Co-administration of the optimized H5N1 influenza hemagglutinin (HA) polypeptides facilitates synergistic neutralization of viral infection and provides for improved protective immunity (e.g., a broad reactive immune response) to multiple H5N1 influenza virus clades and strains.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: February 4, 2020
    Assignees: Oregon Health & Science University, Sanofi Pasteur, Inc.
    Inventors: Ted Milburn Ross, Tim Alefantis, Donald Martin Carter, Christopher Austin Darby, Harold Kleanthous
  • LASER THERMAL CONJUNCTIVOPLASTY
    Publication number: 20200030141
    Abstract: Disclosed is a handheld laser probe for laser thermal conjunctivoplasty, the handheld laser comprising: a forceps; and a line focused laser light source coupled to the forceps, wherein the forceps are configured to grasp a conjunctival fold and hold the fold in a light beam of the line focused laser, and wherein the line focused laser beam is configured to uniformly heat the conjunctival fold held in the forceps. Disclosed are systems for laser thermal conjunctivoplasty including the handheld laser. Disclosed are methods of conjunctivoplasty using the handheld laser probe.
    Type: Application
    Filed: February 27, 2018
    Publication date: January 30, 2020
    Applicant: Oregon Health & Science University
    Inventors: David Huang, Gangjun Liu, Jianlong Yang, Stephen Pflugfelder
  • Derivatives of sobetirome
    Patent number: 10544075
    Abstract: Disclosed are halo substituted derivative compounds of sobetirome with improved pharmacological characteristics relative to sobetirome, pharmaceutical compositions that include those compounds and methods of treating diseases such as neurodegenerative disorders using those pharmaceutical compositions.
    Type: Grant
    Filed: May 18, 2017
    Date of Patent: January 28, 2020
    Assignee: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Thomas Scanlan, Jordan Devereaux, Andrew Placzek, Tapasree Banerji, Skylar Ferrara, James Matthew Meinig, Tania Banerji
  • Quinolone-3-diarylethers
    Patent number: 10532983
    Abstract: Disclosed are derivative compounds of ELQ-300 that include an ester at position 4. These compounds have enhanced properties relative to ELQ-300. Also disclosed are pharmaceutical compositions comprising the compounds and methods of treating and preventing malaria infections involving administering the pharmaceutical compositions to the subject.
    Type: Grant
    Filed: July 20, 2016
    Date of Patent: January 14, 2020
    Assignee: Oregon Health & Science University
    Inventors: Michael Riscoe, Aaron Nilsen, Galen Miley, Rolf Winter, Sovitj Pou, Jane Xu Kelly, Rozalia Dodean
  • Cytomegalovirus vectors eliciting T cells restricted by major histocompatibility complex E molecules
    Patent number: 10532099
    Abstract: Disclosed are CMV vectors that lack active UL128, UL130, UL146 and UL147 proteins that may also comprise one or more microRNA regulatory elements (MRE) that restrict expression of the CMV. Immunization with the disclosed CMV vectors allow selection of different CD8+ T cell responses—CD8+ T cells restricted by MHC-Ia, MHC-II, or by MHC-E.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: January 14, 2020
    Assignee: OREGON HEALTH & SCIENCE UNIVERSITY
    Inventors: Louis Picker, Scott Hansen, Klaus Frueh, Daniel Malouli, Jay Nelson, Jonah Sacha, Meaghan Hancock
  • Methods of treating inflammatory or autoimmune disorders with compounds that bind macrophage migration inhibitory factor
    Patent number: 10525101
    Abstract: Recombinant polypeptides, pharmaceutical compositions comprising recombinant polypeptides, and methods of treating autoimmune and/or inflammatory diseases using the pharmaceutical compositions are disclosed. The polypeptides are based upon the trimerization and/or MIF binding domains of CD74.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: January 7, 2020
    Assignees: Oregon Health & Science University, The United States Government as Represented by the Department of Veterans Affairs
    Inventors: Arthur A. Vandenbark, Gil Benedek, Roberto Meza-Romero
  • Hand function diagnostic and therapeutic system
    Patent number: 10517513
    Abstract: Systems, devices and methods for quantitatively assessing hand function strength and range of motion via various instrumentations are disclosed. In one example embodiment, a hand function diagnostic and therapeutic system includes distal and proximal finger flexion measurement apparatuses used to automate quantitative assessment of hand function based on a combination of strength, range of motion, and time performance metrics.
    Type: Grant
    Filed: October 30, 2015
    Date of Patent: December 31, 2019
    Assignee: Oregon Health & Science University
    Inventors: Yves Vimegnon, Gregory Landry